Abstract Background The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported. Methods Patients were randomized 1:1 to olaparib plus radium‐223 (arm A) or radium‐223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer The
Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib
Rana R. McKay·Geoffrey I. Shapiro·Archana Ajmera·Arlene Araneta·Edmund Folefac·Arif Hussain·Christos E. Kyriakopoulos·Adam Olson·Mamta Parikh·Rahul Parikh·Biren Saraiya·W. Xie